biostudies-literatureNapolitano AV-FoundationNCI DODNCIWellcome Trust and the Medical Research CouncilMedical Research CouncilNIMHD NIH HHSNCI NIH HHSUniversity of Hawaii Foundation Honeywell International Inc.Belluck and Fox, and the Stephen E. Banner FoundationThe Riviera United 4-a Cure, and Mesothelioma Applied Research Foundation and Shino-Test CorporationWellcome TrustEDRN NCI3087-96https://www.ebi.ac.uk/biostudies/studies/S-EPMC4867109biostudies-literatureUnknown22(12)<h4>Purpose</h4>To determine whether serum levels of high mobility group box protein 1 (HMGB1) could differentiate malignant mesothelioma patients, asbestos-exposed individuals, and unexposed controls.<h4>Experimental design</h4>Hyperacetylated and nonacetylated HMGB1 (together referred to as total HMGB1) were blindly measured in blood collected from malignant mesothelioma patients (n = 22), individuals with verified chronic asbestos exposure (n = 20), patients with benign pleural effusions (n = 13) or malignant pleural effusions not due to malignant mesothelioma (n = 25), and healthy controls (n = 20). Blood levels of previously proposed malignant mesothelioma biomarkers fibulin-3, mesothelin, and osteopontin were also measured in nonhealthy individuals.<h4>Results</h4>HMGB1 serum levels Clinical cancer research : an official journal of the American Association for Cancer ResearchHMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.PMC4867109U01 CA1112955U01CA111295–08R01106567R01 CA198138G0700654NCI-R01 CA160715, DOD CA120355U54 MD007584MR/L006758/1R01 CA160715P30 CA071789Yang HNapolitano APellegrini LPastorino SPass HIProkrym KCanino CGoparaju CMCarbone MBaumann FAntoine DJPagano IfalseHMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.<h4>Purpose</h4>To determine whether serum levels of high mobility group box protein 1 (HMGB1) could differentiate malignant mesothelioma patients, asbestos-exposed individuals, and unexposed controls.<h4>Experimental design</h4>Hyperacetylated and nonacetylated HMGB1 (together referred to as total HMGB1) were blindly measured in blood collected from malignant mesothelioma patients (n = 22), individuals with verified chronic asbestos exposure (n = 20), patients with benign pleural effusions (n = 13) or malignant pleural effusions not due to malignant mesothelioma (n = 25), and healthy controls (n = 20). Blood levels of previously proposed malignant mesothelioma biomarkers fibulin-3, mesothelin, and osteopontin were also measured in nonhealthy individuals.<h4>Results</h4>HMGB1 serum levels 2016-01-01T00:00:00Z2016 Jun2025-04-05T14:58:53.737Z2019-03-27T02:13:39ZS-EPMC48671092673361610.1158/1078-0432.CCR-15-113010.1158/1078-0432.ccr-15-1130